{"groups":[{"description":"Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle","id":"FG000","title":"Lenalidomide 25mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"181"}],"type":"Progression of Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"46"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"40"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Lack of therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"330"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"330"}],"type":"Safety Population"},{"achievements":[{"comment":"Completed = those who completed the treatment phase and were ongoing in the extension study","groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"309"}],"type":"NOT COMPLETED"}],"title":"Treatment Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lack of therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"NOT COMPLETED"}],"title":"Extension Phase"}],"preAssignmentDetails":"To be eligible participants must have developed disease progression or were unable to tolerate the lowest dosing regimen of thalidomide and/or high-dose dexamethasone without Grade 3 or 4 toxicity","recruitmentDetails":"This was an international, open-label single arm study of oral lenalidomide in participants with multiple myeloma who had previously received high dose dexamethasone alone or in combination with thalidomide in the study NCT 00057564, or previously received high dose dexamethasone alone in studies NCT 00056160 and NCT 00424047."}